Amal Khouri Sells 5,000 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of C$5.75, for a total value of C$28,750.00.

Amal Khouri also recently made the following trade(s):

• On Thursday, July 11th, Amal Khouri sold 10,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.70, for a total transaction of C$57,000.00.
• On Wednesday, July 3rd, Amal Khouri sold 10,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.72, for a total transaction of C$57,200.00.
• On Monday, June 10th, Amal Khouri sold 20,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.80, for a total transaction of C$116,022.00.

Knight Therapeutics Price Performance

Shares of GUD stock traded down C$0.05 during mid-day trading on Wednesday, reaching C$5.69. The company’s stock had a trading volume of 9,109 shares, compared to its average volume of 64,570. The company has a debt-to-equity ratio of 9.20, a quick ratio of 1.79 and a current ratio of 3.34. The firm’s 50-day moving average is C$5.66 and its two-hundred day moving average is C$5.64. Knight Therapeutics Inc. has a 1-year low of C$4.35 and a 1-year high of C$6.22. The company has a market cap of C$576.85 million, a P/E ratio of -35.88, a PEG ratio of -1,013.50 and a beta of 0.46.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Stifel Nicolaus raised Knight Therapeutics from a “hold” rating to a “buy” rating and lifted their target price for the stock from C$5.75 to C$6.75 in a research report on Tuesday. Stifel Canada upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.